Sorafenib
Multi-kinase tablet for liver, kidney and thyroid cancers.
- Starts working
- Depends on the cancer and regimen
- Half-life
- 25–48 hours
- In use since
- —
- Pregnancy
- Usually avoided
Overview
Sorafenib blocks several kinases involved in tumour growth and blood supply. Hand-foot skin reaction and high blood pressure are common.
Conditions it's used for
How it works
Slows tumour growth and blood supply.
Sorafenib belongs to the Tyrosine kinase inhibitors. How Tyrosine kinase inhibitors work: block a faulty 'on switch' protein that a cancer depends on.
Uses
- Hepatocellular (liver) cancer
- Advanced kidney cancer
- Differentiated thyroid cancer
Available as: tablet.
Typical dose
- Adults
- Dosed by your cancer team according to the treatment protocol.
- Good to know
- Doses depend on body size, blood counts and the regimen.
Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.
Side effects
Common
Often mild and may settle with time
- Hand-foot skin reaction
- Diarrhoea
- High blood pressure
- Rash
- Tiredness
Serious — get medical help
Uncommon, but need prompt attention
- Bleeding
- Heart problems
- Liver injury
- Bowel perforation
Warnings
- Take on an empty stomach or with a low-fat meal
Who should avoid it
- Pregnancy
- Uncontrolled high blood pressure
Interactions
- Warfarin — INR changes
- Rifampicin, St John's wort — lower levels
- Docetaxel, doxorubicin — raised levels
Other medicines in the atlas that need care with Sorafenib, grouped by the reason:
Reduced effectModerateWith Carbamazepine, Efavirenz, Enzalutamide, Griseofulvin, Modafinil and 5 more
Enzyme induction lowers levels of this medicine, which may stop it working.
What's usually done: Monitor effect; dose changes or alternatives may be needed. The effect lasts weeks after stopping the inducer.
Raised drug levelsModerateWith Clarithromycin, Darunavir, Erythromycin, Itraconazole, Lopinavir-ritonavir and 2 more
Blocking CYP3A4 increases levels of this medicine, so side effects become more likely.
What's usually done: A dose reduction, alternative or extra monitoring may be needed.
Using it safely
- Alcohol
- Best to limit. Alcohol may add to liver strain.
- Food and drink
- Take on an empty stomach or with a low- to moderate-fat meal.
- If you miss a dose
- Skip and take the next dose as normal.
- Stopping it
- Only on advice of your cancer team.
- Driving
- Tiredness may affect driving.
- Tests and checks
- Blood pressure; Skin of hands and feet; Liver tests
- If too much is taken
- Seek medical advice.
- Storage
- Room temperature.
- Legal status
- United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule HAustralia: Prescription only (Schedule 4)
Pregnancy and breastfeeding
Pregnancy
Usually avoided
Avoid.
Breastfeeding
Usually avoided
Avoid.
Special groups
- Kidney disease
- Dose may need adjusting; your team will advise.
- Liver disease
- Dose may need adjusting; your team will advise.
- Older adults
- Older adults may be more sensitive to side effects.
Brand names
- United States
- Nexavar
- United Kingdom
- Nexavar
- India
- Nexavar, Sorafenib (generic), Soranib
- Australia
- Nexavar
Examples only; many generic versions exist. The same brand name can mean different products in different countries.
Common questions
Do I need a prescription for Sorafenib?
Yes — Sorafenib is prescription-only in most countries.
Can I take Sorafenib during pregnancy?
Usually avoided. Avoid. Always check with a doctor or midwife.
How quickly does Sorafenib work?
Depends on the cancer and regimen.
Related medicines
Sunitinib
Multi-kinase capsule for kidney cancer and GIST.
RxWHOTyrosine kinase inhibitorsErlotinib
EGFR tablet for lung cancers with EGFR mutations.
RxWHOTyrosine kinase inhibitorsGefitinib
First-generation EGFR tablet for mutated lung cancer.
RxWHOTyrosine kinase inhibitorsImatinib
Targeted pill that turned a deadly leukaemia into a manageable condition.
RxWHOTyrosine kinase inhibitorsOsimertinib
Targeted pill for EGFR-mutated lung cancer.
RxTyrosine kinase inhibitors
Sources and official information
Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.